BioNTech, Lilly shore up manufacturing capacity for their COVID-19 medsWith vaccines and drugs for COVID-19 now in late-stage development, companies are moving swiftly to lay down the Share XBioNTech, Lilly shore up manufacturing capacity for their COVID-19 medshttps://pharmaphorum.com/news/biontech-lilly-shore-up-manufacturing-capacity-for-their-covid-19-meds/
Eyeing emergency use of COVID-19 drug, Humanigen partners with Lonza to make itHumanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before Share XEyeing emergency use of COVID-19 drug, Humanigen partners with Lonza to make ithttps://pharmaphorum.com/news/eyeing-emergency-use-of-covid-19-drug-humanigen-partners-with-lonza-to-make-it/
Chasing Regeneron, AZ starts trials of its COVID-19 antibody cocktailThe first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that Share XChasing Regeneron, AZ starts trials of its COVID-19 antibody cocktailhttps://pharmaphorum.com/news/chasing-regeneron-az-starts-trials-of-its-covid-19-antibody-cocktail/
Regeneron recruits Roche to make COVID-19 antibody drug REGN-COV2Roche has agreed to help Regeneron manufacture its COVID-19 antibody cocktail REGN-COV2, which started late-stage clinical testing a Share XRegeneron recruits Roche to make COVID-19 antibody drug REGN-COV2https://pharmaphorum.com/news/regeneron-recruits-roche-to-make-covid-19-antibody-drug-regn-cov2/
Roche signs up with Oncimmune to explore immunotherapy responsesRoche has doubled down on a partnership with UK biotech Oncimmune looking at how autoantibodies can affect patients’ Share XRoche signs up with Oncimmune to explore immunotherapy responseshttps://pharmaphorum.com/news/roche-signs-up-with-oncimmune-to-explore-immunotherapy-responses/
Sorrento surges on antibody ‘shield’ trials for coronavirusShares in Sorrento Therapeutics rose 158% on Friday after it revealed plans to start human trials of an Share XSorrento surges on antibody ‘shield’ trials for coronavirushttps://pharmaphorum.com/news/sorrento-surges-on-antibody-shield-trials-for-coronavirus/
Epsilogen licenses first-in-class IgE ovarian cancer drugUK biotech Epsilogen has licensed rights to a drug for solid tumours developed by Kings College London and Share XEpsilogen licenses first-in-class IgE ovarian cancer drughttps://pharmaphorum.com/news/epsilogen-licenses-first-in-class-ige-ovarian-cancer-drug/
Regeneron’s Ebola drug heading for October verdict from FDAThe FDA has kicked off a six-month priority review of REGN-EB3, Regeneron’s three-drug therapy for Ebola virus infection, Share XRegeneron’s Ebola drug heading for October verdict from FDAhttps://pharmaphorum.com/news/regenerons-ebola-drug-heading-for-october-verdict-from-fda/
MorphoSys gets $750m from Incyte for anti-CD19 cancer drugIncyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to Share XMorphoSys gets $750m from Incyte for anti-CD19 cancer drughttps://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/
